B. Campos

Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel

L. León, L. A. Antón Aparicio, S. Vázquez, 2014, Anti-cancer drugs.

Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study

A. Arance, V. Soriano, E. Nagore, 2015, PloS one.

Venous Thromboembolism In Cancer Patients: “From Evidence to Care”

M. Salgado, E. Brozos-Vázquez, B. Campos, 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.

Jorge García, L. Santomé, M. Lázaro, 2022, Cancer treatment and research communications.

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study

R. Garcia-Arroyo, M. Constenla, I. Lorenzo, 2002, Gastric Cancer.

Docetaxel as Single-Agent Treatment in Elderly Patients with Advanced Breast Cancer

L. Salgado, F. García-Arroyo, M. Constenla, 2005, Clinical drug investigation.

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

A. Arance, E. Espinosa, C. Montagut, 2021, Nature Communications.

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .

Ipilimumab in Older Patients: Spanish Melanoma Multidisciplinary Group (GEM) Experience in the Expanded Access Programme

F. Zambrana, M. Sereno, M. G. Cao, 2012 .

Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes.

E. Nadal, M. Dómine, R. Blanco, 2023, Lung cancer.

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

E. Espinosa, L. Fernández-Morales, Á. Rodríguez-Lescure, 2023, Melanoma research.

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.

E. Gallardo, C. Grande, S. Candamio, 2013, Journal of geriatric oncology.